818 COVID-19 patients studied to uncover risk factors for severe disease

NCT ID NCT04887142

Completed Knowledge-focused Sponsor: Zeljko Mijailovic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study enrolled 818 adults hospitalized with COVID-19 to examine how genetic, inflammatory, and other blood markers relate to disease severity and death. Researchers tracked outcomes like recovery or death and analyzed risk factors using statistical models. The goal was to better understand why some patients become severely ill, which could improve future care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors better predict which COVID-19 patients are at highest risk of severe illness or death, potentially guiding more personalized care.
What could go wrong: This is an observational study, not a treatment trial, so it cannot prove cause and effect. The findings may not apply to all populations or future virus variants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Faculty of Medical Sciences, University Clinical Center Kragujevac

Kragujevac, Srbija, 34000, Serbia
General Hospital "Prim. dr. Abdulah Nakaš"

Sarajevo, Bosnia and Herzegovina
KBC Rijeka, University of Rijeka

Rijeka, Croatia
Spitali Amerikan

Tirana, Albania
University of Montenegro, Faculty of Medicine

Podgorica, Montenegro

More trials for these conditions

Other studies related to the condition(s) this trial covers.